Colocalization of transactivation-responsive DNA-binding protein 43 and huntingtin in inclusions of Huntington disease.
about
The function of RNA-binding proteins at the synapse: implications for neurodegenerationHyperphosphorylation as a defense mechanism to reduce TDP-43 aggregationTDP-43 aggregation in neurodegeneration: are stress granules the key?The tau tubulin kinases TTBK1/2 promote accumulation of pathological TDP-43Temporal separation of aggregation and ubiquitination during early inclusion formation in transgenic mice carrying the Huntington's disease mutationPrevention of intestinal obstruction reveals progressive neurodegeneration in mutant TDP-43 (A315T) mice.A neurotoxic phosphoform of Elk-1 associates with inclusions from multiple neurodegenerative diseases.Astrocytic TDP-43 pathology in Alexander diseaseSpinal motor neuron protein supersaturation patterns are associated with inclusion body formation in ALS.TAR DNA-binding protein 43 in neurodegenerative disease.Phosphorylated TDP-43 pathology and hippocampal sclerosis in progressive supranuclear palsyTDP-43 pathology in primary progressive aphasia and frontotemporal dementia with pathologic Alzheimer disease.The influence of pathological mutations and proline substitutions in TDP-43 glycine-rich peptides on its amyloid properties and cellular toxicity.An aggregation sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate inhibitors.Interaction with polyglutamine aggregates reveals a Q/N-rich domain in TDP-43.Dual vulnerability of TDP-43 to calpain and caspase-3 proteolysis after neurotoxic conditions and traumatic brain injuryTDP-43 in aging and Alzheimer's disease - a reviewInhibition of TDP-43 aggregation by nucleic acid bindingTDP-1, the Caenorhabditis elegans ortholog of TDP-43, limits the accumulation of double-stranded RNA.Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43.Gene targeting of mouse Tardbp negatively affects Masp2 expression.Progranulin gene delivery protects dopaminergic neurons in a mouse model of Parkinson's disease.TDP-43-based animal models of neurodegeneration: new insights into ALS pathology and pathophysiology.On the development of markers for pathological TDP-43 in amyotrophic lateral sclerosis with and without dementia.Different 8-hydroxyquinolines protect models of TDP-43 protein, α-synuclein, and polyglutamine proteotoxicity through distinct mechanisms.TDP-43 Inhibits NF-κB Activity by Blocking p65 Nuclear Translocation.TDP-43 protein variants as biomarkers in amyotrophic lateral sclerosis.Coexistence of Huntington's disease and amyotrophic lateral sclerosis: a clinicopathologic study.Parkin ubiquitinates Tar-DNA binding protein-43 (TDP-43) and promotes its cytosolic accumulation via interaction with histone deacetylase 6 (HDAC6).Neurodegeneration the RNA wayThe p.A382T TARDBP gene mutation in Sardinian patients affected by Parkinson's disease and other degenerative parkinsonismsHuntington's Disease Protein Huntingtin Associates with its own mRNA.Lentiviral vector-mediated overexpression of mutant ataxin-7 recapitulates SCA7 pathology and promotes accumulation of the FUS/TLS and MBNL1 RNA-binding proteinsMolecular neuropathology of TDP-43 proteinopathies.Mutations in TDP-43 link glycine-rich domain functions to amyotrophic lateral sclerosis.Amyotrophic lateral sclerosis, frontotemporal dementia and beyond: the TDP-43 diseases.Acute and chronically increased immunoreactivity to phosphorylation-independent but not pathological TDP-43 after a single traumatic brain injury in humans.Identification of an RNA Polymerase III Regulator Linked to Disease-Associated Protein Aggregation.TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration.Coexistence of TDP-43 and tau pathology in neurodegeneration with brain iron accumulation type 1 (NBIA-1, formerly Hallervorden-Spatz syndrome).
P2860
Q26991684-163ACE9F-4C05-4787-BF81-532049B3BB34Q27325625-54BADDD0-A33D-4592-A5C4-964A591B3A1FQ27692111-F8045E5D-63F2-4DBE-ABAF-391AA74017F4Q28542476-D3E6A6F4-2840-4866-9AAF-A22D00FCAC7CQ28728849-D06055BE-B5ED-4DA6-8E29-649892F50C7DQ30583228-C8D231BD-6D04-4C8E-A8EB-D58C0B4DBE6BQ33528960-8C9A4B7A-4960-4087-8A85-1A4B84A7E549Q33575134-339899BF-C95E-4C5A-BD80-B03AB51892B9Q33719399-5EE8F26F-6550-40BA-9F15-CBB054F4CEF5Q33941040-255E0E13-7037-4BE8-9859-AAB9476E563DQ33984304-369358EF-A323-4FAC-82DE-A521E21D50D4Q33992842-2215B016-C7C9-42AA-A04F-4B18CF06D20EQ33999609-B140595E-5C42-4498-AC61-5833E104947AQ34066654-A0E25545-12EA-441C-8935-99C8E64F81F8Q34074385-A2FCE5A4-E2BD-45E5-AD38-2C22EF8CF84BQ34153412-FDA37031-FAAC-47FA-8BEE-3AACBC459A74Q34566756-39A17FAC-587E-4E61-8992-063EF3EEE1C4Q34758540-4EE655C7-D6F1-43B6-9F18-D8D73971EFA5Q34807584-4E57D4BB-1E6A-4BEE-8C7E-8D9959AB40CBQ34982074-FB486ACE-2393-48E6-BBCA-265B5C7ACDEEQ35150738-23EF853E-C5E7-4340-923C-F5D958170934Q35164339-8F4673CD-02CC-4C0B-A4DC-8C962B148AA2Q35546452-1F18363D-5812-45DE-A6C1-2E833919C58EQ35592875-F137CFBF-E546-4B89-876A-E79757247068Q35763165-E1E02F48-789A-4BC0-B396-3B8B0CFDC278Q35842277-83DA6CAC-FB04-425C-BFAE-3E78E6414F15Q36260146-2F59899B-A251-420B-92FC-1D6C121C7992Q36534978-6817E389-BEF9-4D21-A002-504A25136130Q36596241-5ACCF679-7DE9-40BD-8CDC-EBF8D17C21F2Q36638284-2B927C78-B9FD-45E4-9538-A81A2C2463C6Q36865769-A3DC99E1-4F34-4AF9-BC4B-83B55FA95400Q37053914-55B3D595-47C0-4A66-BA06-04D391DE6385Q37133999-680D46A6-3B9A-4A2B-963B-5EB7DEA10274Q37143159-8B17D7E1-5501-46DC-AD66-03A3D4F0C2A8Q37379471-E89C0888-2ECF-45F7-AD24-FE522FC542CBQ37409270-7CD39756-1BB6-442F-B218-A9E30B809E86Q37691547-B1AA5091-6FBA-4DE3-B353-E1D0B3CD6946Q37719263-06A67827-B8EF-472F-9E9D-0C98A92B7AA2Q37733168-CDA23648-38D0-4A49-801B-2C61114755F6Q37833138-56E624D4-435C-4C5C-8011-ACC743A2C007
P2860
Colocalization of transactivation-responsive DNA-binding protein 43 and huntingtin in inclusions of Huntington disease.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Colocalization of transactivat ...... lusions of Huntington disease.
@en
Colocalization of transactivat ...... lusions of Huntington disease.
@nl
type
label
Colocalization of transactivat ...... lusions of Huntington disease.
@en
Colocalization of transactivat ...... lusions of Huntington disease.
@nl
prefLabel
Colocalization of transactivat ...... lusions of Huntington disease.
@en
Colocalization of transactivat ...... lusions of Huntington disease.
@nl
P2093
P2860
P1476
Colocalization of transactivat ...... lusions of Huntington disease.
@en
P2093
Claudia Schwab
Masato Hasegawa
Patrick L McGeer
Tetsuaki Arai
P2860
P304
P356
10.1097/NEN.0B013E31818E8951
P577
2008-12-01T00:00:00Z